{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T04:19:23Z","timestamp":1729829963452,"version":"3.28.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,24]]},"DOI":"10.7759\/cureus.72267","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T11:15:14Z","timestamp":1729768514000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety of Non-vitamin K Antagonist Oral Anticoagulants on Outcomes After Transcatheter Aortic Valve Replacement: An Updated Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Aman","family":"Goyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahammed","family":"Khan Suheb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humza","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mah I Kan","family":"Changez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Daoud","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viraj","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima  Q","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laveeza","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hritvik","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidhartha G","family":"Senapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vamsikalyan","family":"Borra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1514616","article-title":"Transcatheter or surgical aortic-valve replacement in intermediate-risk patients","volume":"374","author":"Leon MB","year":"2016","unstructured":"Leon MB, Smith CR, Mack MJ, et al.. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016, 374:1609-20. 10.1056\/NEJMoa1514616","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR randomized clinical trial","volume":"146","author":"Park DW","year":"2022","unstructured":"Park DW, Ahn JM, Kang DY, et al.. Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR randomized clinical trial. Circulation. 2022, 146:466-79. 10.1161\/CIRCULATIONAHA.122.059512","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon MB","year":"2010","unstructured":"Leon MB, Smith CR, Mack M, et al.. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010, 363:1597-607. 10.1056\/NEJMoa1008232","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients","volume":"364","author":"Smith CR","year":"2011","unstructured":"Smith CR, Leon MB, Mack MJ, et al.. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011, 364:2187-98. 10.1056\/NEJMoa1103510","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation","volume":"382","author":"Nijenhuis VJ","year":"2020","unstructured":"Nijenhuis VJ, Brouwer J, Delewi R, et al.. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med. 2020, 382:1696-707. 10.1056\/NEJMoa1915152","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem NM","year":"2021","unstructured":"Van Mieghem NM, Unverdorben M, Hengstenberg C, et al.. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021, 385:2150-60. 10.1056\/NEJMoa2111016","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al.. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013, 369:2093-104. 10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2021.09.019","article-title":"Subclinical leaflet thrombosis after transcatheter aortic valve replacement: a meta-analysis","volume":"14","author":"Bogyi M","year":"2021","unstructured":"Bogyi M, Schernthaner RE, Loewe C, et al.. Subclinical leaflet thrombosis after transcatheter aortic valve replacement: a meta-analysis. JACC Cardiovasc Interv. 2021, 14:2643-56. 10.1016\/j.jcin.2021.09.019","journal-title":"JACC Cardiovasc Interv"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009, 151:264-9, W64. 10.7326\/0003-4819-151-4-200908180-00135","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs255","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document","volume":"33","author":"Kappetein AP","year":"2012","unstructured":"Kappetein AP, Head SJ, G\u00e9n\u00e9reux P, et al.. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J. 2012, 33:2403-18. 10.1093\/eurheartj\/ehs255","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran R","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, et al.. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011, 123:2736-47. 10.1161\/CIRCULATIONAHA.110.009449","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet JP","year":"2022","unstructured":"Collet JP, Van Belle E, Thiele H, et al.. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022, 43:2783-97. 10.1093\/eurheartj\/ehac242","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2016.10.023","article-title":"Apixaban in patients with atrial\u00a0fibrillation\u00a0after transfemoral aortic\u00a0valve\u00a0replacement","volume":"10","author":"Seeger J","year":"2017","unstructured":"Seeger J, Gonska B, Rodewald C, Rottbauer W, W\u00f6hrle J. Apixaban in patients with atrial\u00a0fibrillation\u00a0after transfemoral aortic\u00a0valve\u00a0replacement. JACC Cardiovasc Interv. 2017, 10:66-74. 10.1016\/j.jcin.2016.10.023","journal-title":"JACC Cardiovasc Interv"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2019.03.003","article-title":"Oral anticoagulant type and outcomes\u00a0after transcatheter aortic\u00a0valve replacement","volume":"12","author":"Jochheim D","year":"2019","unstructured":"Jochheim D, Barbanti M, Capretti G, et al.. Oral anticoagulant type and outcomes\u00a0after transcatheter aortic\u00a0valve replacement. JACC Cardiovasc Interv. 2019, 12:1566-76. 10.1016\/j.jcin.2019.03.003","journal-title":"JACC Cardiovasc Interv"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvz064","article-title":"Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation","volume":"7","author":"Butt JH","year":"2021","unstructured":"Butt JH, De Backer O, Olesen JB, et al.. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2021, 7:11-9. 10.1093\/ehjcvp\/pvz064","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2021.05.025","article-title":"TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist?","volume":"14","author":"Didier R","year":"2021","unstructured":"Didier R, Lhermusier T, Auffret V, et al.. TAVR patients requiring anticoagulation: direct oral anticoagulant or vitamin K antagonist?. JACC Cardiovasc Interv. 2021, 14:1704-13. 10.1016\/j.jcin.2021.05.025","journal-title":"JACC Cardiovasc Interv"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-018-1247-x","article-title":"NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation","volume":"107","author":"Geis NA","year":"2018","unstructured":"Geis NA, Kiriakou C, Chorianopoulos E, Uhlmann L, Katus HA, Bekeredjian R. NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation. Clin Res Cardiol. 2018, 107:799-806. 10.1007\/s00392-018-1247-x","journal-title":"Clin Res Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2020.09.013","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR","volume":"13","author":"Kawashima H","year":"2020","unstructured":"Kawashima H, Watanabe Y, Hioki H, et al.. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation after TAVR. JACC Cardiovasc Interv. 2020, 13:2587-97. 10.1016\/j.jcin.2020.09.013","journal-title":"JACC Cardiovasc Interv"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2019.06.001","article-title":"Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation","volume":"12","author":"Kosmidou I","year":"2019","unstructured":"Kosmidou I, Liu Y, Alu MC, et al.. Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve replacement in patients with atrial fibrillation. JACC Cardiovasc Interv. 2019, 12:1580-9. 10.1016\/j.jcin.2019.06.001","journal-title":"JACC Cardiovasc Interv"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-019-01968-w","article-title":"Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry","volume":"50","author":"Kalogeras K","year":"2020","unstructured":"Kalogeras K, Jabbour RJ, Ruparelia N, et al.. Comparison of warfarin versus DOACs in patients with concomitant indication for oral anticoagulation undergoing TAVI; results from the ATLAS registry. J Thromb Thrombolysis. 2020, 50:82-9. 10.1007\/s11239-019-01968-w","journal-title":"J Thromb Thrombolysis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023561","article-title":"Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: insights from the STS\/ACC TVT Registry","volume":"11","author":"Tanawuttiwat T","year":"2022","unstructured":"Tanawuttiwat T, Stebbins A, Marquis-Gravel G, Vemulapalli S, Kosinski AS, Cheng A. Use of direct oral anticoagulant and outcomes in patients with atrial fibrillation after transcatheter aortic valve replacement: insights from the STS\/ACC TVT Registry. J Am Heart Assoc. 2022, 11:e023561. 10.1161\/JAHA.121.023561","journal-title":"J Am Heart Assoc"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2018.12.042","article-title":"Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implantation and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation","volume":"123","author":"Mangner N","year":"2019","unstructured":"Mangner N, Crusius L, Haussig S, et al.. Continued versus interrupted oral anticoagulation during transfemoral transcatheter aortic valve implantation and impact of postoperative anticoagulant management on outcome in patients with atrial fibrillation. Am J Cardiol. 2019, 123:1134-41. 10.1016\/j.amjcard.2018.12.042","journal-title":"Am J Cardiol"},{"key":"ref25","unstructured":"Report finds TAVR is dominant form of aortic valve replacement, outcomes steadily improving in the United States. (2020). Accessed. June 30, 2024: https:\/\/www.acc.org\/about-acc\/press-releases\/2020\/11\/16\/18\/53\/report-finds-tavr-is-dominant-form-of-aortic-valve-repl...."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613792","article-title":"Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement","volume":"377","author":"Goldstone AB","year":"2017","unstructured":"Goldstone AB, Chiu P, Baiocchi M, Lingala B, Patrick WL, Fischbein MP, Woo YJ. Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N Engl J Med. 2017, 377:1847-57. 10.1056\/NEJMoa1613792","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11082190","article-title":"Antithrombotic therapy following transcatheter aortic valve replacement","volume":"11","author":"Granger C","year":"2022","unstructured":"Granger C, Guedeney P, Collet JP. Antithrombotic therapy following transcatheter aortic valve replacement. J Clin Med. 2022, 11:2190. 10.3390\/jcm11082190","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-020-01582-2","article-title":"Efficacy and safety outcomes in novel oral anticoagulants versus vitamin-K antagonist on post-TAVI patients: a meta-analysis","volume":"20","author":"Liang H","year":"2020","unstructured":"Liang H, He Q, Zhang Q, Liu X, Cui K, Chen G, Xiu J. Efficacy and safety outcomes in novel oral anticoagulants versus vitamin-K antagonist on post-TAVI patients: a meta-analysis. BMC Cardiovasc Disord. 2020, 20:307. 10.1186\/s12872-020-01582-2","journal-title":"BMC Cardiovasc Disord"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.12.039","article-title":"Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists after transcatheter aortic valve implantation","volume":"125","author":"Ueyama H","year":"2020","unstructured":"Ueyama H, Kuno T, Ando T, Briasoulis A, Fox J, Hayashida K, Takagi H. Meta-analysis comparing direct oral anticoagulants versus vitamin K antagonists after transcatheter aortic valve implantation. Am J Cardiol. 2020, 125:1102-7. 10.1016\/j.amjcard.2019.12.039","journal-title":"Am J Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-022-03371-6","article-title":"A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation","volume":"78","author":"Ooi AJ","year":"2022","unstructured":"Ooi AJ, Wong C, Tan TW, et al.. A systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulants vs vitamin K antagonists after transcatheter aortic valve replacement in patients with atrial fibrillation. Eur J Clin Pharmacol. 2022, 78:1589-600. 10.1007\/s00228-022-03371-6","journal-title":"Eur J Clin Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231158585","article-title":"Comparing vitamin K antagonists and direct oral anticoagulants in patients with atrial fibrillation undergoing transcatheter aortic valve replacement: a meta-analysis","volume":"29","author":"Lee WC","year":"2023","unstructured":"Lee WC, Shih JY, Fang HY, et al.. Comparing vitamin K antagonists and direct oral anticoagulants in patients with atrial fibrillation undergoing transcatheter aortic valve replacement: a meta-analysis. Clin Appl Thromb Hemost. 2023, 29:10760296231158585. 10.1177\/10760296231158585","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.11.008","article-title":"Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation","volume":"173","author":"Nijenhuis VJ","year":"2016","unstructured":"Nijenhuis VJ, Bennaghmouch N, Hassell M, et al.. Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation. Am Heart J. 2016, 173:77-85. 10.1016\/j.ahj.2015.11.008","journal-title":"Am Heart J"},{"key":"ref33","unstructured":"Antithrombotic therapy after TAVI. insights provided by the POPULAR-TAVI trial. (2021). Accessed: June 30, 2024: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2021\/02\/08\/14\/06\/Antithrombotic-Therapy-After-TAVI#:~:text=Current%...."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-22-0093","article-title":"Edoxaban vs. vitamin K antagonist for atrial fibrillation after transcatheter aortic valve replacement in Japanese patients-a subanalysis of the ENVISAGE-TAVI AF trial","volume":"86","author":"Watanabe Y","year":"2022","unstructured":"Watanabe Y, Hayashida K, Yamamoto M, et al.. Edoxaban vs. vitamin K antagonist for atrial fibrillation after transcatheter aortic valve replacement in Japanese patients-a subanalysis of the ENVISAGE-TAVI AF trial. Circ J. 2022, 86:1756-63. 10.1253\/circj.CJ-22-0093","journal-title":"Circ J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.062","article-title":"Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)","volume":"63","author":"Flaker G","year":"2014","unstructured":"Flaker G, Lopes RD, Al-Khatib SM, et al.. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014, 63:1082-7. 10.1016\/j.jacc.2013.09.062","journal-title":"J Am Coll Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004267","article-title":"Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)","volume":"10","author":"Link MS","year":"2017","unstructured":"Link MS, Giugliano RP, Ruff CT, et al.. Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circ Arrhythm Electrophysiol. 2017, 10:e004267. 10.1161\/CIRCEP.116.004267","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/clc.23178","article-title":"Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial","volume":"42","author":"Guimar\u00e3es PO","year":"2019","unstructured":"Guimar\u00e3es PO, Pokorney SD, Lopes RD, et al.. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol. 2019, 42:568-71. 10.1002\/clc.23178","journal-title":"Clin Cardiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000001908","article-title":"Efficacy and outcomes of antiplatelet therapy versus oral anticoagulants in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis","volume":"86","author":"Goyal A","year":"2024","unstructured":"Goyal A, Abbasi FQ, Tariq MD, et al.. Efficacy and outcomes of antiplatelet therapy versus oral anticoagulants in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis. Ann Med Surg (Lond). 2024, 86:2911-25. 10.1097\/MS9.0000000000001908","journal-title":"Ann Med Surg (Lond)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/273024-safety-of-non-vitamin-k-antagonist-oral-anticoagulants-on-outcomes-after-transcatheter-aortic-valve-replacement-an-updated-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T11:15:18Z","timestamp":1729768518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/273024-safety-of-non-vitamin-k-antagonist-oral-anticoagulants-on-outcomes-after-transcatheter-aortic-valve-replacement-an-updated-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.72267","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,24]]}}}